SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish a prospective, single-center platform research
based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive
HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.